SAREPTA THERAPEUTICS, INC. Liabilities, Fair Value Adjustment
SAREPTA THERAPEUTICS, INC. (SRPT) reported Liabilities, Fair Value Adjustment of $25.60 million for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-06.
Financial Statements › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
us-gaap:LiabilitiesFairValueAdjustment · last filed 2025-11-06
- SAREPTA THERAPEUTICS, INC. liabilities, fair value adjustment for the quarter ending 2025-09-30 was $25.60M, a 3100.00% increase year-over-year.
- SAREPTA THERAPEUTICS, INC. liabilities, fair value adjustment for the quarter ending 2025-03-31 was $10.10M, a 0.00% change year-over-year.
- SAREPTA THERAPEUTICS, INC. liabilities, fair value adjustment for the quarter ending 2024-12-31 was $0.00.
- SAREPTA THERAPEUTICS, INC. liabilities, fair value adjustment for the quarter ending 2024-09-30 was $800.00K, a 60.00% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. liabilities, fair value adjustment for fiscal 2024 was $9.30M, a 675.00% increase from fiscal 2023.
- SAREPTA THERAPEUTICS, INC. liabilities, fair value adjustment for fiscal 2023 was $1.20M.
- SAREPTA THERAPEUTICS, INC. liabilities, fair value adjustment for fiscal 2022 was -$6.70M.
- SAREPTA THERAPEUTICS, INC. liabilities, fair value adjustment for fiscal 2021 was -$7.20M, a 116.00% decline from fiscal 2020.
| Period end | Liabilities, Fair Value Adjustment 3 month | Liabilities, Fair Value Adjustment 3 month as first filed | Liabilities, Fair Value Adjustment 6 month | Liabilities, Fair Value Adjustment 9 month | Liabilities, Fair Value Adjustment 9 month as first filed | Liabilities, Fair Value Adjustment 12 month |
|---|---|---|---|---|---|---|
| 2025-09-30 | $25.60M 10-Q · filed 2025-11-06 | $14.50M 10-Q · filed 2025-11-06 | ||||
| 2025-03-31 | $10.10M 10-Q · filed 2025-05-06 | $10.10M derived: sum of 2 quarters · filed 2025-05-06 | $10.90M derived: sum of 3 quarters · filed 2025-11-06 | $10.90M derived: sum of 4 quarters · filed 2025-11-06 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $800.00K derived: sum of 2 quarters · filed 2025-11-06 | $800.00K derived: sum of 3 quarters · filed 2025-11-06 | $9.30M 10-K · filed 2025-02-28 | ||
| 2024-09-30 | $800.00K 10-Q · filed 2025-11-06 | $800.00K derived: sum of 2 quarters · filed 2025-11-06 | $9.30M 10-Q · filed 2025-11-06 | $10.90M derived: sum of 4 quarters · filed 2025-11-06 | ||
| 2024-06-30 | $0.00 10-Q · filed 2024-08-07 | $10.10M 10-Q · filed 2025-08-06 | $10.10M derived: sum of 3 quarters · filed 2025-02-28 | $12.10M derived: sum of 4 quarters · filed 2025-02-28 | ||
| 2024-03-31 | $10.10M 10-Q · filed 2024-05-01 | $10.10M derived: sum of 2 quarters · filed 2025-02-28 | $12.10M derived: sum of 3 quarters · filed 2025-02-28 | $11.30M derived: sum of 4 quarters · filed 2025-02-28 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $2.00M derived: sum of 2 quarters · filed 2025-02-28 | $1.20M derived: sum of 3 quarters · filed 2025-02-28 | $1.20M 10-K · filed 2025-02-28 | ||
| 2023-09-30 | $2.00M 10-Q · filed 2024-11-06 | $1.20M 10-Q · filed 2023-11-01 | $1.20M derived: sum of 2 quarters · filed 2024-11-06 | $1.20M 10-Q · filed 2024-11-06 | $2.00M 10-Q · filed 2023-11-01 | $1.20M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | -$800.00K 10-Q · filed 2024-08-07 | -$800.00K 10-Q · filed 2024-08-07 | -$800.00K derived: sum of 3 quarters · filed 2024-08-07 | -$7.50M derived: sum of 4 quarters · filed 2024-08-07 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-01 | $0.00 derived: sum of 2 quarters · filed 2024-05-01 | -$6.70M derived: sum of 3 quarters · filed 2024-05-01 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$6.70M derived: sum of 2 quarters · filed 2024-02-28 | -$6.70M 10-K · filed 2024-02-28 | |||
| 2022-09-30 | -$6.70M 10-Q · filed 2022-11-02 | -$6.70M 10-Q · filed 2022-11-02 | ||||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-02 | -$14.40M derived: sum of 2 quarters · filed 2023-05-02 | -$7.20M derived: sum of 3 quarters · filed 2023-05-02 | |||
| 2021-12-31 | -$14.40M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$7.20M derived: sum of 2 quarters · filed 2023-02-28 | -$7.20M 10-K · filed 2023-02-28 | |||
| 2021-09-30 | $7.20M 10-Q · filed 2021-11-03 | $7.20M 10-Q · filed 2021-11-03 | ||||
| 2020-12-31 | $45.00M 10-K · filed 2022-03-01 | |||||
| 2020-09-30 | $45.00M 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |